FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107798417> ?p ?o ?g. }

• W2107798417 abstract "Angiogenesis plays a role in tumor growth and is partly mediated by factors in both the fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) pathways. Durable clinical responses with VEGF tyrosine kinase inhibitors (TKIs) may be limited by intrinsic tumor resistance. We hypothesized that FGF signaling may impact clinical responses to sorafenib. Nephrectomy material was available from 40 patients with metastatic renal cell carcinoma (RCC) enrolled in a phase II clinical trial of sorafenib ± interferon (ClinicalTrials.gov Identifier NCT00126594). Fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor receptor substrate 2 alpha (FRS2α) expression was assessed by in situ hybridization and immunofluorescence, respectively. The relationship between fibroblast growth factor pathway marker levels and progression-free survival (PFS) was analyzed using Kaplan-Meier and Cox proportional hazards regression methods. Univariate analysis indicated that more intense FGFR1 staining was associated with shorter PFS (log-rank P = 0.0452), but FRS2α staining was not significantly associated with PFS (log-rank P = 0.2610). Multivariate Cox proportional hazards regression models were constructed for FGFR1 and FRS2α individually, adjusting for baseline Eastern Cooperative Oncology Group performance status, treatment arm and anemia status. When adjusted for each of these variables, the highest intensity level of FGFR1 (level 3 or 4) had increased progression risk relative to the lowest intensity level of FGFR1 (level 1) (P = 0.0115). The highest intensity level of FRS2α (level 3 or 4) had increased progression risk relative to the lowest intensity level of FRS2α (level 1) (P = 0.0126). Increased expression of FGFR1 and FRS2α was associated with decreased PFS among patients with metastatic RCC treated with sorafenib. The results suggest that FGF pathway activation may impact intrinsic resistance to VEGF receptor inhibition." @default.
• W2107798417 created "2016-06-24" @default.
• W2107798417 creator A5007689146 @default.
• W2107798417 creator A5021008372 @default.
• W2107798417 creator A5031600120 @default.
• W2107798417 creator A5041087708 @default.
• W2107798417 creator A5058650905 @default.
• W2107798417 creator A5069230926 @default.
• W2107798417 creator A5075130252 @default.
• W2107798417 creator A5082148006 @default.
• W2107798417 creator A5089628178 @default.
• W2107798417 date "2015-04-18" @default.
• W2107798417 modified "2023-09-22" @default.
• W2107798417 title "The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma" @default.
• W2107798417 cites W1968657935 @default.
• W2107798417 cites W1970171529 @default.
• W2107798417 cites W1974685704 @default.
• W2107798417 cites W1977999028 @default.
• W2107798417 cites W1988717588 @default.
• W2107798417 cites W1999193852 @default.
• W2107798417 cites W2000366267 @default.
• W2107798417 cites W2029464256 @default.
• W2107798417 cites W2031563027 @default.
• W2107798417 cites W2036418044 @default.
• W2107798417 cites W2057038864 @default.
• W2107798417 cites W2057207170 @default.
• W2107798417 cites W2081056357 @default.
• W2107798417 cites W2099938880 @default.
• W2107798417 cites W2109732202 @default.
• W2107798417 cites W2113332865 @default.
• W2107798417 cites W2113375488 @default.
• W2107798417 cites W2125311018 @default.
• W2107798417 cites W2127385754 @default.
• W2107798417 cites W2131593307 @default.
• W2107798417 cites W2150575159 @default.
• W2107798417 cites W2151492809 @default.
• W2107798417 cites W2170552969 @default.
• W2107798417 cites W2171961428 @default.
• W2107798417 cites W2188830923 @default.
• W2107798417 doi "https://doi.org/10.1186/s12885-015-1302-1" @default.
• W2107798417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4406182" @default.
• W2107798417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25900027" @default.
• W2107798417 hasPublicationYear "2015" @default.
• W2107798417 type Work @default.
• W2107798417 sameAs 2107798417 @default.
• W2107798417 citedByCount "15" @default.
• W2107798417 countsByYear W21077984172015 @default.
• W2107798417 countsByYear W21077984172016 @default.
• W2107798417 countsByYear W21077984172017 @default.
• W2107798417 countsByYear W21077984172018 @default.
• W2107798417 countsByYear W21077984172019 @default.
• W2107798417 countsByYear W21077984172020 @default.
• W2107798417 countsByYear W21077984172021 @default.
• W2107798417 countsByYear W21077984172022 @default.
• W2107798417 countsByYear W21077984172023 @default.
• W2107798417 crossrefType "journal-article" @default.
• W2107798417 hasAuthorship W2107798417A5007689146 @default.
• W2107798417 hasAuthorship W2107798417A5021008372 @default.
• W2107798417 hasAuthorship W2107798417A5031600120 @default.
• W2107798417 hasAuthorship W2107798417A5041087708 @default.
• W2107798417 hasAuthorship W2107798417A5058650905 @default.
• W2107798417 hasAuthorship W2107798417A5069230926 @default.
• W2107798417 hasAuthorship W2107798417A5075130252 @default.
• W2107798417 hasAuthorship W2107798417A5082148006 @default.
• W2107798417 hasAuthorship W2107798417A5089628178 @default.
• W2107798417 hasBestOaLocation W21077984171 @default.
• W2107798417 hasConcept C126322002 @default.
• W2107798417 hasConcept C143998085 @default.
• W2107798417 hasConcept C170493617 @default.
• W2107798417 hasConcept C2778019345 @default.
• W2107798417 hasConcept C2778695046 @default.
• W2107798417 hasConcept C49418065 @default.
• W2107798417 hasConcept C502942594 @default.
• W2107798417 hasConcept C50382708 @default.
• W2107798417 hasConcept C71924100 @default.
• W2107798417 hasConcept C74373430 @default.
• W2107798417 hasConceptScore W2107798417C126322002 @default.
• W2107798417 hasConceptScore W2107798417C143998085 @default.
• W2107798417 hasConceptScore W2107798417C170493617 @default.
• W2107798417 hasConceptScore W2107798417C2778019345 @default.
• W2107798417 hasConceptScore W2107798417C2778695046 @default.
• W2107798417 hasConceptScore W2107798417C49418065 @default.
• W2107798417 hasConceptScore W2107798417C502942594 @default.
• W2107798417 hasConceptScore W2107798417C50382708 @default.
• W2107798417 hasConceptScore W2107798417C71924100 @default.
• W2107798417 hasConceptScore W2107798417C74373430 @default.
• W2107798417 hasIssue "1" @default.
• W2107798417 hasLocation W21077984171 @default.
• W2107798417 hasLocation W21077984172 @default.
• W2107798417 hasLocation W21077984173 @default.
• W2107798417 hasLocation W21077984174 @default.
• W2107798417 hasOpenAccess W2107798417 @default.
• W2107798417 hasPrimaryLocation W21077984171 @default.
• W2107798417 hasRelatedWork W1499770494 @default.
• W2107798417 hasRelatedWork W1990357663 @default.
• W2107798417 hasRelatedWork W2051893611 @default.
• W2107798417 hasRelatedWork W2095538986 @default.
• W2107798417 hasRelatedWork W2331750244 @default.
• W2107798417 hasRelatedWork W2409987903 @default.
• W2107798417 hasRelatedWork W2921848022 @default.

• next